...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith funding???

Toinv - What we do know is that ZCC had about US$83,000 cash on Jan. 31st. Up to that date the 9 month average burn rate was about US$800,000/month and the 3 month average burn rate was about US$860,000/month. That tells me that ZCC could be US$4 million or a little more in the red by June 30th. That tells me that there is something going on behind the scenes that we don't know about to allow ZCC to continue operating under these conditions and maybe even start a new trial. They aren't going to tell us what it is until they are ready to so all we can do is accept that, stew over it or speculate what it is. All I can say is that someone is allowing the company to keep operating for some reason with no announced way to cover the increasing debt. Is something in the wind?

Share
New Message
Please login to post a reply